|Day Low/High||49.03 / 50.13|
|52 Wk Low/High||49.04 / 77.12|
Bristol-Myers Squibb Company (NYSE:BMY) today announced new results from CheckMate -205, a multi-cohort, single-arm, Phase 2 trial evaluating Opdivo (nivolumab) in patients with classical Hodgkin lymphoma (cHL).
Bristol-Myers Squibb's (NYSE:BMY) Coast 2 Coast 4 Cancer has raised more than $1,050,000 to support Stand Up To Cancer's collaborative cancer research programs.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Here's your 'silver linings playbook' for what promises to be a nerve-wracking week of unpredictable politics, mixed corporate earnings and volatile energy prices.
Flood of earnings, data and reports restrains the market, with no help from Wednesday's debate. We added to one of our portfolio positions.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2016 on Thursday, October 27, 2016.
The drug titan reports Tuesday. Will a Dec. 24 cancer drug approval be an early Christmas gift?
Vale may be worth following again. Bristol-Myers? Not so much.
Cramer says P&G is a good choice and is disappointed by Bristol-Myers Squibb.
A malaise has once again befallen America, Cramer says.
Today the Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care.
We took advantage of several down days during the week to add to a recently added position.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment...
Bristol-Myers (BMY) stock rating was maintained at 'buy' at Goldman Sachs.
If nothing else, the beginning of earnings season should provide a bit more consistent price action.
Election and rate hike concerns did not stop retail investors from stepping up their equity exposure in September, especially in popular stocks like Facebook and Tesla.
U.S. stocks are higher Monday thanks to a rally in crude oil.
It's time to take a break from the traditional methods of generating investment ideas; let's just follow the crowd.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.
We recommend members avoid selling into panic, however, and reiterate our 18-24-month time horizon.
U.S. stocks rise Monday as Wall Street looks past Sunday's presidential debate and eyes oil and earnings.
Bristol-Myers (BMY) stock is slumping on Monday after Merck (MRK) issued results from its Keytruda drug trial, which showed it was more effective than chemotherapy in reducing patients' lung cancer.